Low dose IL-2 therapy restores regulatory T cells in patients with systemic lupus erythematosus in a dose-dependent manner: a phase IIb trial

Abstract Low-dose interleukin 2 (Ld-IL2) has shown therapeutic effects in autoimmune diseases, particularly systemic lupus erythematosus (SLE), yet optimal dosage has not been established in clinical trials. In this multicentre, double-blind, phase IIb trial, 152 patients with active SLE were random...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Xia Zhang, Ruiling Feng, Yifan Wang, Wenqiang Fan, Xiao Gao, Miaomiao Ma, Guanmin Gao, Dongbin Jiang, Ting Li, Huifang Guo, Lingyan Lei, Ke Xu, Yucui Li, Kuanting Wang, Yan Ding, Wei Wei, Na Zhang, Wenping Pan, Qingwen Wang, Juan He, Yueming Cai, Tongjun Mao, Ruijun Zhang, Rong Mu, Yongfu Wang, Hui Wang, Yuan Jia, Xiaolin Sun, Zhanguo Li, Jing He
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Nature Portfolio 2026-04-01
Edice:	Nature Communications
On-line přístup:	https://doi.org/10.1038/s41467-026-72245-7
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!